Sanguine, a technology company enabling personalized medical research for the development of new and effective treatments, announced an agreement with Mayo Clinic Bioservices. Under this agreement, Mayo Clinic Bioservices will process, store and ship biospecimens that Sanguine has collected for clients developing new therapies. This will dramatically increase Sanguine’s capacity and scalability, allowing the company to serve more clients simultaneously.Mayo Clinic Bioservices will provide integrated laboratory services that are vital to basic, translational and epidemiological research, including specimen accessioning, processing, nucleic acid extraction, specimen tracking, storage and shipping. Mayo Clinic Bioservices is a new service from the Mayo Clinic Center for Individualized Medicine with locations at Mayo’s Minnesota, Florida, and Arizona campuses.
“We are excited about the pilot project with Mayo, not only because it increases the scalability of our business, but also because it allows individuals that have been on our waiting list to participate in the research and development of new treatments,” said Brian Neman, CEO of Sanguine. “Mayo Clinic Bioservices has tremendous infrastructure and processing capacity that will meet our existing needs while also offering the potential for future expansion.”
Sanguine bridges the gap between individuals interested in participating in biomedical research and the companies and institutions developing new clinical treatments. Sanguine’s products and services offer transparency, convenience and participant engagement, as the company works to digitize and streamline the biomedical research enrollment process. Examples include electronic informed consent, remote screening, and automated scheduling of home phlebotomy appointments.
The company’s latest product is a mobile application that connects study phlebotomists with potential research participants. The app allows phlebotomists to enter a personalized schedule and then offers available blood-donation times to interested study participants. The app has attracted a network of participants in more than 16 cities across the United States, and interest in this approach continues to grow.
“In addition to allowing us to better serve our existing network of participating individuals, this collaboration allows Sanguine to provide more comprehensive services for our clients, which already include 20 of the top 40 pharmaceutical and biotechnology companies,” Neman said. “Our primary goal is to facilitate development of new therapeutic options for patients and their care providers by linking individuals interested in making a difference with the companies and institutions that develop new treatments. This collaboration with Mayo Clinic is another step in making that process more efficient and thereby getting new therapies to patients.”
Date: April 16, 2014
Source: Sanguine
Filed Under: Drug Discovery
